Is Vumerity Associated with Thrombocytopenia?
No, Vumerity (diroximel fumarate) is not associated with thrombocytopenia based on the FDA drug label and clinical trial data. Thrombocytopenia is not listed as a known adverse effect of this medication.
Key Safety Profile of Vumerity
The FDA-approved drug label for Vumerity 1 and extensive clinical trial data 2, 3 do not identify thrombocytopenia as an adverse reaction. The primary hematologic concern with Vumerity is lymphopenia, not thrombocytopenia.
Documented Hematologic Effects
Lymphopenia is the main blood count abnormality associated with Vumerity:
- Mean lymphocyte counts decrease by approximately 30% during the first year of treatment, then stabilize 1
- 6% of patients experience lymphocyte counts <0.5 × 10⁹/L
- 2% develop prolonged severe lymphopenia (counts <0.5 × 10⁹/L for ≥6 months) 1
Required monitoring includes:
- Complete blood count (CBC) with lymphocyte count before initiating treatment
- Repeat at 6 months after starting treatment
- Then every 6-12 months thereafter 1
Clinical Trial Safety Data
In the EVOLVE-MS-1 study with over 1,000 patients and up to 2 years of exposure 2:
- 88.7% experienced adverse events, mostly mild to moderate
- Only 8.0% discontinued due to adverse events
- Primary adverse events were gastrointestinal (though improved compared to dimethyl fumarate) and flushing
- No mention of thrombocytopenia as an adverse event
Important Clinical Distinction
The provided guidelines on thrombocytopenia 4, 5 discuss evaluation of low platelet counts from other causes (ITP, heparin-induced thrombocytopenia, drug-induced thrombocytopenia). While these guidelines mention that drug-induced thrombocytopenia should always be considered with any medication, Vumerity is not among the drugs commonly or uncommonly associated with this complication.
If thrombocytopenia develops in a patient taking Vumerity, investigate alternative causes including other medications, infections, autoimmune conditions, or hematologic disorders rather than attributing it to the fumarate therapy.